Related Experiment Video

Updated: Jun 17, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Understanding and circumventing resistance to anticancer monoclonal antibodies

Lina Reslan1, Stéphane Dalle, Charles Dumontet

  • 1Inserm U590, Lyon, France.

Mabs
|January 13, 2010
PubMed

Insights

Monoclonal antibody therapy for cancer can become ineffective due to resistance. Understanding resistance mechanisms and exploring new strategies like combination immunotherapy are crucial for improving treatment outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Therapeutic monoclonal antibodies (mAbs) are widely used in cancer treatment.
  • Resistance to mAbs is a significant clinical challenge, limiting treatment efficacy.
  • Mechanisms of resistance involve complex tumor-associated and host factors.

Purpose of the Study:

  • To review mechanisms of action and resistance to rituximab (an mAb).
  • To discuss resistance to other therapeutic monoclonal antibodies.
  • To present innovative strategies for overcoming mAb resistance.

Main Methods:

  • Literature review of preclinical and clinical data on mAb action and resistance.
  • Focus on rituximab, with comparative insights from other mAbs.
  • Exploration of novel therapeutic approaches.

Main Results:

  • Resistance to monoclonal antibodies is multifactorial, involving tumor and host elements.
  • The precise mechanisms of mAb-induced cancer cell death and resistance development require further elucidation.
  • Combination immunotherapy and cytokine/growth factor costimulation show promise.

Conclusions:

  • Further research is needed to fully understand monoclonal antibody efficacy and resistance.
  • Innovative strategies are being developed to overcome treatment resistance.
  • Combination approaches may enhance the effectiveness of monoclonal antibody therapy in cancer patients.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...